IRIS
FABRAZZO, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.469
NA - Nord America 3.296
AS - Asia 509
SA - Sud America 46
Continente sconosciuto - Info sul continente non disponibili 4
AF - Africa 2
OC - Oceania 2
Totale 8.328
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.288
IT - Italia 1.247
IE - Irlanda 1.093
UA - Ucraina 577
GB - Regno Unito 437
FR - Francia 275
SE - Svezia 274
DE - Germania 228
CN - Cina 217
FI - Finlandia 148
SG - Singapore 147
TR - Turchia 103
GR - Grecia 96
BR - Brasile 44
PL - Polonia 21
BE - Belgio 20
RU - Federazione Russa 13
IN - India 12
CH - Svizzera 11
ES - Italia 7
IR - Iran 7
CA - Canada 6
KR - Corea 6
HK - Hong Kong 5
NL - Olanda 5
EU - Europa 4
JP - Giappone 4
AE - Emirati Arabi Uniti 3
CZ - Repubblica Ceca 3
CO - Colombia 2
EG - Egitto 2
HU - Ungheria 2
LT - Lituania 2
NO - Norvegia 2
PT - Portogallo 2
RO - Romania 2
TW - Taiwan 2
AT - Austria 1
AU - Australia 1
IL - Israele 1
IS - Islanda 1
JO - Giordania 1
MX - Messico 1
NZ - Nuova Zelanda 1
PA - Panama 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 8.328
Salva come PNG Salva come JPEG
Città #
Dublin 1.076
Jacksonville 877
Chandler 542
Princeton 172
Roxbury 136
Ann Arbor 96
Medford 91
Cambridge 89
Woodbridge 89
Ashburn 87
Singapore 87
Boardman 83
Caserta 72
Wilmington 69
Bremen 68
Beijing 65
Rome 58
Naples 56
Milan 52
San Mateo 49
Nanjing 43
New York 37
Des Moines 33
Seattle 32
Düsseldorf 27
Aversa 21
Norwalk 20
Brussels 19
Mountain View 18
Padova 17
Jinan 16
Napoli 16
Catania 15
Marigliano 15
Houston 13
Radomsko 13
Torino 13
Fisciano 12
Shenyang 12
Auburn Hills 9
Bologna 9
Florence 9
Nanchang 9
Palermo 9
Salerno 9
Bari 8
Como 8
Genova 8
Helsinki 8
Perugia 8
Tianjin 8
Catanzaro 7
Kunming 7
Cava de' Tirreni 6
Hangzhou 6
Los Angeles 6
Pune 6
Seoul 6
Somma 6
Turin 6
Dalmine 5
Genoa 5
Haikou 5
Ningbo 5
Parma 5
Redwood City 5
Rio Saliceto 5
Taizhou 5
Verona 5
Adelfia 4
Bagnoli Irpino 4
Bergamo 4
Bern 4
Cagliari 4
Cassano Magnago 4
Castelvetrano 4
Cedar Knolls 4
Ferrara 4
Groningen 4
Hong Kong 4
Jesi 4
Lanzhou 4
Moscow 4
Pisa 4
Scafati 4
Silver Spring 4
São Paulo 4
Venezia 4
Zhengzhou 4
Abu Dhabi 3
Atella 3
Bertinoro 3
Borgo San Lorenzo 3
Cascina 3
Castelnuovo Rangone 3
Changchun 3
Edinburgh 3
Ercolano 3
Fairfield 3
Guangzhou 3
Totale 4.622
Salva come PNG Salva come JPEG
Nome #
SINDROME METABOLICA E TRATTAMENTO CON ANTIPSICOTICI: DIFFERENZE IN PAZIENTI CON DIAGNOSI DI SCHIZOFRENIA E DISTURBO BIPOLARE 412
Discrasie ematiche transitorie e persistenti indotte dalla clozapina durante le prime diciotto settimane di trattamento 251
CLOZAPINA E ALTRI ANTIPSICOTICI ATIPICI E TIPICI: INCIDENZA E DECORSO DELLE DISCRASIE EMATICHE DURANTE LE PRIME DICIOTTO SETTIMANE DI TRATTAMENTO 178
Trattamento combinato con clorimipramina ed aripiprazolo nella depressione resistente 127
TRATTAMENTO CON ANTIPSICOTICI E COMPARSA DI SINDROME METABOLICA: UNO STUDIO RETROSPETTIVO IN PAZIENTI SCHIZOFRENICI E BIPOLARI 111
Sindrome metabolica e utilizzo di antipsicotici in pazienti con diagnosi di schizofrenia e disturbo bipolare 87
Brain natriuretic peptide as a biomarker of asymptomatic clozapine-related heart dysfunction: a criterion for a more cautious administration. 87
Magnetic resonance imaging of a transient splenial lesion of the corpus callosum resolved within a week 86
Cancro della mammella e Alessitimia: Freno o Incentivo alla prevenzione? 85
Central and peripheral peptides regulating eating behaviour and energy homeostasis in anorexia nervosa and bulimia nervosa: a literature review 76
Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs 75
Trattamento con antipsicotici e sindrome metabolica: uno studio retrospettivo in pazienti schizofrenici e bipolari 74
La depressione resistente al trattamento farmacologico: incremento dell’effetto antidepressivo della clorimipramina determinato dall’aripiprazolo 74
Discrasie ematiche transitorie e persistenti e trattamento con clozapina nelle prime diciotto settimane di terapia 68
From over- to under-weight: treatment of post-surgical anorexia nervosa in morbid obesity 67
Molecular Psychiatry: regulation of gene function 66
Investigation of peptide YY and ghrelin responses to a test meal in bulimia nervosa. 65
Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment 64
Serotonin transporter polymorphism and potential response to SSRIs in bulimia nervosa 63
L’Olanzapina è più rapida dell’Aloperidolo nell’indurre Sindrome Metabolica in pazienti schizofrenici ma non nei bipolari 61
Risposta al trattamento con inibitori del reuptake della serotonina nel disturbo ossessivo-compulsivo ad esordio precoce 60
Transient and persistent blood dyscrasias induced by clozapine during the first 18 weeks of treatment 60
Clozapine versus other antipsychotics during the first 18 weeks of treatment: A retrospective study on risk factor increase of blood dyscrasias 60
A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa 59
Leptin production in Bulimia Nervosa 58
Duration of untreated illness and outcome of obsessive-compulsive disorder: A naturalistic follow-up study. 58
Circulating ghrelin is decreased in non-obese and obese women with binge eating disorder as well as in obese non-binge eating women, but not in patients with bulimia nervosa 57
Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine 57
Antipsychotic treatment and metabolic syndrome: a retrospective study in schizophrenic and bipolar patients 57
Il trattamento farmacologico dei sintomi negativi della schizofrenia 57
Antipsychotic Treatment and Metabolic Syndrome: a Comparison between Schizophrenic and Bipolar Patients. 57
Correlati neurofisiologici della risposta clinica ai neurolettici tipici in pazienti schizofrenici al primo episodio di malattia 56
I neurosteroidi ed il recettore periferico delle benzodiazepine 56
Studio longitudianle dei livelli plasmatici del cortisolo e delle catecolamine e della risposta al test al desametazone in pazienti con disordine affettivo bipolare 56
Brain-derived neurotrophic factor (BDNF) nello spettro del comportamento alimentare 56
In rats the reserpine induced increase of brain NGF biosynthesis is mediated by corticosteroids 56
Metabolic Syndrome and Antipsychotic treatment: how about schizophrenia and bipolar disorder? 56
Aumento dei livelli plasmatici di colesterolo e trigliceridi nella bulimia nervosa 54
Changes of cholinergic, noradrenergic and serotonergic synaptic transmission indices elicited by Ethylcholine Aziridinium ion (AF64A) infused intraventricularly 53
Steroid regulation of Nerve Growth Factor biosynthesis in the CNS 53
Antipsychotic treatment and metabolic syndrome: a retrospective study in schizophrenic and bipolar patients 53
Il monitoraggio plasmatico della clozapina e dei suoi principali metaboliti in pazienti schizofrenici 53
Are antipsychotics useful in the treatment of anorexia nervosa? A review of the literature 53
Blood levels of mianserin and amitriptyline and clinical response in aged depressed patients 52
Long-term pharmacological treatment in schizophrenia 51
Pemphigus and skin disease: A comparison of the incidence of stressful life events and personality disorders 51
Effect of treatment duration on plasma levels of clozapine and n-desmethylclozapine in men and women 51
Livelli plasmatici di TNF alfa in pazienti schizofrenici 51
Sciatic nerves transplanted into the CNS exhibit elevated nerve growth factor (NGF) protein levels 51
Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients 51
Il monitoraggio plasmatico della clozapina e dei suoi principali metaboliti in pazienti schizofrenici 50
The role of drug therapies in the treatment of anorexia and bulimia nervosa: a review of the literature 49
La sindrome metabolica e l’utilizzo di antipsicotici: quali differenze in schizofrenia e disturbo bipolare? 49
L'anoressia mentale: aspetti eziopatogenetici clinici e terapeutici 49
L'ansia , la depressione e il movimento nell'anziano 49
Plasma leptin and soluble leptin receptor in patients with eating disorders 49
Add-on oral olanzapine worsens hallucinations in schizoaffective disorder. 48
Regulation of nerve growth factor receptor mRNA content by dexamethasone: in vitro and in vivo studies 48
Clozapina ed SSRI: indicazioni cliniche ed interazioni farmacocinetiche 48
Transcriptional regulation of Nerve Growth Factor gene 48
Una strategia di trattamento combinato con cloripramina ed aripiprazolo nella depressione resistente 48
Livelli plasmatici degli aminoacidi nei pazienti affetti da schizofrenia cronica. 48
Pheripheral peptides regulating meal initiation and termination in bulimia nervosa 48
Pharmacology of Nerve Growth Factor biosynthesis in rat brain 48
Transsynaptic regulation of nerve growth factor gene expression 48
Comorbidity of obsessive-compulsive disorder and schizotypal personality disorder: Clinical response and treatment resistance to pharmacotherapy in a 3-year follow-up naturalistic study 48
Opposite modifications in circulating leptin and solubile leptin receptor across the eating disorder spectrum 47
Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment 47
Regulation of Nerve Growth Factor receptor biosynthesis: in vitro and in vivo studies 47
Altered ghrelin physiology in bulimia nervosa: integration with leptin changes 47
Gli endocannabinoidi nei disturbi del comportamento alimentare: implicazioni fisiopatologiche 47
Neonatal mild stress influences the programming of some adult cerebral biochemical structures 47
Duration of untreated illness and outcome of the OCD: a three-year prospective study 47
Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature 47
Decreased blood levels of tumor necrosis factor-alpha in patients with obsessive-compulsive disorder 46
Peripheral ghrelin and PYY responses to food intake and short-term fasting: implications for eating behaviour and gastrointestinal physiology in bulimia nervosa 46
Clozapine treatment and other atypical and typical antipsychotics: incidence and course of blood dyscrasias during the first eighteen weeks of treatment 46
Induction of Nerve Growth Factor gene expression by Beta-adrenergic receptor activation 46
Response to lithium prophylaxis in schizoaffective psychoses 45
Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure 45
Use of clozapine in a patient with schizophrenia and polidipsia 45
Toward a pharmacology of Nerve Growth Factor (NGF) biosynthesis 45
Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia 44
Neuroendocrine findings in obsessive-compulsive disorder: implications for drug treatment 44
Effects of sciatic nerve transplants after fimbria-fornix lesion: examination of the role of nerve growth factor 44
LA BULIMIA E I DISTURBI CORRELATI: ASPETTI EZIOPATOGENETICI, CLINICI E TERAPEUTICI 44
Clinical and neurophysiological findings in schizophrenic patients with enlarged and normal ventricles 44
Livelli plasmatici di ghrelina in donne obese e non obese con binge eating disorder, donne obese senza binge eating disorder e pazienti con bulimia nervosa 44
Safety and Tolerability of Mood Stabilisers 44
Peripheral peptides in patients with bulimia nervosa and bing eating disorder 43
Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: An open preliminary study. 43
Circulating brain-derived neurotrophic factor is decreased in women with anorexia and bulimia nervosa but not in women with binge eating disorder: relationships to comorbid depression, psychopathology and hormonal variables 42
Time courses of clozapine response and clozapine plasma levels: a one-year prospective study in drug resistant schizophrenic patients 42
Disturbo ossessivo-compulsivo ad esordio precoce: caratteristiche cliniche e risposta al trattamento 42
Immunoendocrine findings in patients with eating disorders 41
Stimulation of nerve growth factor biosynthesis in developing rat brain by reserpine: steroids as potential mediators 41
Olanzapine is faster than Haloperidol in inducing Metabolic Syndrome in schizophrenics but not in bipolar patients 41
Transient and persistent blood dyscrasias induced by clozapine treatment 41
Long-term treatment with clozapine does not affect morning circulating levels of allopregnanolone and THDOC in patients with schizophrenia: a preliminary study 40
Correlazione tra risposta clicnica e livelli plasmatici di clozapina e principali metaboliti in un trial standardizzato 40
Totale 6.109
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.731
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.731
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020915 0 182 46 13 158 30 189 67 77 77 57 19
2020/20211.412 111 9 173 117 227 23 176 153 18 197 146 62
2021/20221.198 70 7 21 38 435 20 25 44 53 61 90 334
2022/20232.183 187 59 48 160 259 182 4 124 1.042 17 54 47
2023/2024991 80 27 81 76 287 58 35 60 14 26 84 163
2024/202541 22 19 0 0 0 0 0 0 0 0 0 0
Totale 8.489